According to Phase 3 trial results in the New England Journal of Medicine , this rash affected 0.8% of participants after the first dose, and 0.2% of participants after the second shot
Ozkan S, Jindal S, Greenseid K, Shu J, Zeitlian G, Hickmon C, et al
Its lightweight, non-greasy formula is suitable for all skin types and ideal for daily use, morning and night
UpToDate.Uptodate.com
Different cellular and pathological disorders including calcium imbalance, altered mitochondrial dynamics, impaired biogenesis, oxidative stress, defective mitophagy, impaired mitochondrial trafficking, and dysfunctional respiratory chain lead to the development of mitochondrial dysfunction with subsequent progression of PD due to degeneration of DNs (Fig